Related Experiment Video
Updated: Aug 22, 2025

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse
Christina R Washington1, Kathleen N Moore2
1Stephenson Cancer Center, University of Oklahoma HSC, 800 NE 10th St, Suite 5050, Oklahoma City, OK, 73104, USA. Christina-washington@ouhsc.edu.
Purpose Of Review:
This review will focus on the most common mechanisms for poly (ADP-ribose) polymerase inhibitors' (PARPi) resistance and the main strategies for overcoming acquired or de novo PARPi resistance.
Recent Findings:
Initial approvals for PARPi as part of treatment for advanced epithelial ovarian cancer (EOC) started in 2014 with patient with recurrent cancer characterized by BRCA mutations in the 3rd and 4th line and now have approvals for front-line maintenance in both the BRCA mutated and BRCAwt populations. As with all therapies, patients will eventually develop resistance to treatment. The most common mechanisms for PARPi resistance include reversion mutations, methylation events, and restoration of homologous recombination deficiency (HRD) through combinations and targeting replication stress. As more and more patients receive initial treatment (and potential retreatment with PARPi), we need to better understand the mechanisms in which tumors acquire PARPi resistance.
More Related Videos
Related Concept Videos
Restarting Stalled Replication Forks
Treatment Resistant Cancers
Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
DNA Damage can Stall the Cell Cycle
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. ...
Proofreading
Errors During Replication are Corrected by the DNA Polymerase...

